Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jan 10;40(2):138-149.
doi: 10.1200/JCO.21.01752. Epub 2021 Oct 26.

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

Robert L Ferris  1 , Yael Flamand  2 , Gregory S Weinstein  3 , Shuli Li  2 , Harry Quon  4 , Ranee Mehra  5 , Joaquin J Garcia  6 , Christine H Chung  7 , Maura L Gillison  8 , Umamaheswar Duvvuri  1 , Bert W O'Malley Jr  3 , Enver Ozer  9 , Giovana R Thomas  10 , Wayne M Koch  4 , Neil D Gross  8 , R Bryan Bell  11 , Nabil F Saba  12 , Miriam Lango  13 , Eduardo Méndez  14   15 , Barbara Burtness  16
Affiliations
Clinical Trial

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

Robert L Ferris et al. J Clin Oncol. .

Abstract

Purpose: Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC.

Methods: E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index.

Results: Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented.

Conclusion: Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.

PubMed Disclaimer

Conflict of interest statement

Robert L. FerrisThis author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: NovasentaConsulting or Advisory Role: Merck, Pfizer, EMD Serono, Numab, Macrogenics, Aduro Biotech, Novasenta, Sanofi, Zymeworks, Bristol Myers SquibbResearch Funding: Bristol Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, Novasenta Gregory S. WeinsteinPatents, Royalties, Other Intellectual Property: Olympus Shuli LiEmployment: TakedaStock and Other Ownership Interests: Takeda Harry QuonEmployment: Johns Hopkins HospitalLeadership: Pistevo HealthStock and Other Ownership Interests: Oncospace, Pistevo HealthHonoraria: Sanofi/RegeneronConsulting or Advisory Role: Pinnacle Biologics, Tactile MedicalResearch Funding: Toshiba, Vibrent HealthPatents, Royalties, Other Intellectual Property: Filed under Hopkins, we have several patents related to mobile informatics solutionsOther Relationship: EPIC Ranee MehraStock and Other Ownership Interests: GlaxoSmithKline (I)Consulting or Advisory Role: Bayer, Rakuten MedicalResearch Funding: AstraZeneca, Merck Christine H. ChungConsulting or Advisory Role: Bristol Myers Squibb, CUE Biopharma, Mirati Therapeutics, Sanofi/Regeneron, ExelixisResearch Funding: AstraZeneca, Bristol Myers Squibb, Lilly, Merck, Regeneron, Ignyta, Pfizer, Brooklyn ImmunoTherapeutics, Iovance BiotherapeuticsTravel, Accommodations, Expenses: AstraZeneca, Mirati Therapeutics Maura L. GillisonConsulting or Advisory Role: Bristol Myers Squibb, Merck, EMD Serono, Kura Oncology, BioNTech, Shattuck Labs, Bayer, Debiopharm Group¸ Ipsen, Gilead Sciences¸ Bicara Therapeutics, Nektar¸ Istari, LLX Solutions, OncLive, Seagen, Kura Oncology, Mirati Therapeutics, Sensei BiotherapeuticsResearch Funding: Bristol Myers Squibb, Genocea Biosciences, Cullinan Oncology, Genentech, Agenus, Kura Oncology Umamaheswar DuvvuriConsulting or Advisory Role: ACTIVARTIS BiotechResearch Funding: Kolltan Pharmaceuticals, Medrobotics Bert W. O'Malley JrPatents, Royalties, Other Intellectual Property: Receive royalties from University of Pennsylvania via a licensed technology to Olympus Inc Neil D. GrossHonoraria: Intuitive SurgicalConsulting or Advisory Role: PDS Biotechnology, Verb Surgical, Sanofi/Regeneron, Shattuck LabsResearch Funding: Regeneron, MedImmune, GenentechPatents, Royalties, Other Intellectual Property: UpToDate R. Bryan BellHonoraria: Merck, RegeneronConsulting or Advisory Role: MacrogenicsSpeakers' Bureau: Merck, RegeneronResearch Funding: Bristol Myers Squibb/Celgene Nabil F. SabaHonoraria: Merck, CUE Biopharma, BioNTech AG, GlaxoSmithKlineResearch Funding: Bristol-Myers Squibb, ExelixisTravel, Accommodations, Expenses: Merck, Pfizer, Blueprint Medicines Barbara BurtnessConsulting or Advisory Role: Merck, Debiopharm Group, CUE Biopharma, Maverick Therapeutics, Rakuten Medical, Nanobiotix, Macrogenics, ALX Oncology, IO Biotech, Ipsen, Genentech/Roche, Kura Oncology, Merck KGaA, PPD Global, ExelixisResearch Funding: Merck (Inst), Aduro Biotech (Inst), Formation Biologics (Inst), Bristol Myers (Inst), CUE Biopharma (Inst)Travel, Accommodations, Expenses: Merck, Debiopharm GroupNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
CONSORT diagram.
FIG 2.
FIG 2.
Kaplan-Meier estimates of PFS by arm for 359 evaluable patients. PFS, progression-free survival.
FIG 3.
FIG 3.
Kaplan-Meier estimates of OS by arm for 359 evaluable patients. OS, overall survival.
FIG 4.
FIG 4.
(A) Swallowing and (B) QOL. QOL, quality of life; Trt and/or Obs, treatment and/or observation; Tx, treatment.
FIG A1.
FIG A1.
Kaplan-Meier estimates of PFS for 71 ineligible and step 2 treated patients. PFS, progression-free survival.
FIG A2.
FIG A2.
Kaplan-Meier estimates of OS for 71 ineligible and step 2 treated patients. OS, overall survival.
FIG A3.
FIG A3.
Kaplan-Meier estimates of PFS for 430 step 2 treated patients (eligible and ineligible combined). PFS, progression-free survival.
FIG A4.
FIG A4.
Kaplan-Meier estimates of OS for 430 step 2 treated patients (eligible and ineligible combined). OS, overall survival.
See this image and copyright information in PMC

Comment in

References

    1. Adelstein DJ, Ridge JA, Brizel DM, et al. : Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. Head Neck 34: 1681–17032012 - PMC - PubMed
    1. Ang KK, Harris J, Wheeler R, et al. : Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24–352010 - PMC - PubMed
    1. D'Souza G, Kreimer AR, Viscidi R, et al. : Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944–19562007 - PubMed
    1. Holsinger FC, Ferris RL: Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: Robotics, lasers, and clinical trials. J Clin Oncol 33: 3285–32922015 - PMC - PubMed
    1. O'Sullivan B, Huang SH, Su J, et al. : Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): A multicentre cohort study. Lancet Oncol 17: 440–4512016 - PubMed

Publication types

MeSH terms